Monte Sereno, California
United States
54
2022-08-18
The entities that hold a legal rights for patent applications filed by inventor MILLER Guy M.:
Guy M. MILLER from Monte Sereno, US has applied for patents for these inventions. The list has both pending applications and granted patents:
METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS
#2 | 2022-05-05TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
#3 | 2022-02-24REDOX-ACTIVE THERAPEUTICS FOR TREATMENT OF MITOCHONDRIAL DISEASES AND OTHER CONDITIONS AND MODULATION OF ENERGY BIOMARKERS
#4 | 2021-10-21TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
#5 | 2021-05-20TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONES
#6 | 2021-05-06TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH REDOX-ACTIVE THERAPEUTICS
#7 | 2020-04-23METHODS AND COMPOSITIONS FOR TREATMENT OF INFLAMMATION AND OXIDATIVE STRESS
#8 | 2019-07-18TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
#9 | 2019-03-21Treatment of pervasive developmental disorders with redox-active therapeutics
#10 | 2018-12-06METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
#11 | 2018-11-22VITAMIN E COMPOSITIONS AND METHODS OF USE THEREFOR
#12 | 2018-10-25TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONES
#13 | 2018-10-25TREATMENT OF OXIDATIVE STRESS DISORDERS INCLUDING CONTRAST NEPHROPATHY, RADIATION DAMAGE AND DISRUPTIONS IN THE FUNCTION OF RED CELLS
#14 | 2018-07-19TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS
#15 | 2018-05-03FORMULATIONS OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
#16 | 2017-12-14FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
#17 | 2017-08-31TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
#18 | 2017-06-08Treatment of pervasive developmental disorders with redox-active therapeutics
#19 | 2017-05-04Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
#20 | 2017-01-12METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
#21 | 2016-11-10TREATMENT OF MITOCHONDRIAL DISEASES
#22 | 2016-08-25Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
#23 | 2015-08-27Treatment of pervasive developmental disorders with redox-active therapeutics
#24 | 2015-08-06QUINONE DERIVATIVES FOR USE IN THE MODULATION OF REDOX STATUS OF INDIVIDUALS
#25 | 2015-02-26TREATMENT OF METHYLMALONIC ACIDURIA, ISOVALERIC ACIDURIA, AND OTHER ORGANIC ACIDURIAS WITH TOCOTRIENOL QUINONES
#26 | 2014-11-20TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
#27 | 2014-09-04TREATMENT OF HEARING AND BALANCE IMPAIRMENTS WITH REDOX-ACTIVE THERAPEUTICS
#28 | 2014-07-24Treatment of pervasive developmental disorders with redox-active therapeutics
#29 | 2014-02-06Treatment of leber's hereditary optic neuropathy and dominant optic atrophy with tocotrienol quinones
#30 | 2014-01-30FORMULATIONS OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
#31 | 2014-01-30TREATMENT OF MITOCHONDRIAL DISEASES WITH VITAMIN K
#32 | 2013-12-26TREATMENT OF MITOCHONDRIAL DISEASES WITH NAPHTHOQUINONES
#33 | 2013-10-10TREATMENT OF MITOCHONDRIAL DISEASES
#34 | 2013-05-02FORMULATIONS OF QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
#35 | 2013-02-28Treatment of pervasive developmental disorders with redox-active therapeutics
#36 | 2012-11-22METHODS FOR IMPROVING BLOOD GLUCOSE CONTROL
#37 | 2012-05-31TOPICAL, PERIOCULAR, OR INTRAOCULAR USE OF TOCOTRIENOLS FOR THE TREATMENT OF OPHTHALMIC DISEASES
#38 | 2012-05-17TREATMENT OF PERVASIVE DEVELOPMENTAL DISORDERS WITH TOCOTRIENOLS OR TOCOTRIENOL ENRICHED EXTRACTS
#39 | 2011-11-03Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
#40 | 2011-08-25METHODS FOR THE PREVENTION AND TREATMENT OF CEREBRAL ISCHEMIA
#41 | 2011-07-14TREATMENT OF LEIGH SYNDROME AND LEIGH-LIKE SYNDROME WITH TOCOTRIENOL QUINONES
#42 | 2011-06-16TREATMENT OF HEARING AND BALANCE IMPAIRMENTS USING COMPOUNDS HAVING ERYTHROPOIETIN ACTIVITY
#43 | 2010-10-28TREATMENT OF LEBER'S HEREDITARY OPTIC NEUROPATHY AND DOMINANT OPTIC ATROPHY WITH TOCOTRIENOL QUINONES
#44 | 2010-10-28FORMULATIONS OF TOCOTRIENOL QUINONES FOR THE TREATMENT OF OPHTHALMIC DISEASES
#45 | 2010-09-02Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
#46 | 2010-03-11Treatment of pervasive developmental disorders with redox-active therapeutics
#47 | 2010-03-04TREATMENT OF RESPIRATORY CHAIN DISORDERS USING COMPOUNDS HAVING ERYTHROPOIETIN OR THROMBOPOIETIN ACTIVITY
#48 | 2010-02-04NAPHTHOQUINONE COMPOSITIONS WITH ANTI-AGING, ANTI-INFLAMMATORY AND SKIN EVEN-TONING PROPERTIES
#49 | 2010-02-04HYDROGENATED PYRIDO[4,3-b]INDOLES FOR THE TREATMENT OF OXIDATIVE STRESS
#50 | 2010-01-14DERMATOLOGICAL COMPOSITIONS WITH ANTI-AGING AND SKIN EVEN-TONING PROPERTIES
#51 | 2009-11-26TREATMENT OF MITOCHONDRIAL DISEASES WITH AN ERYTHROPOIETIN MIMETIC
#52 | 2009-06-25IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
#53 | 2009-06-25IDENTIFYING THERAPEUTIC COMPOUNDS BASED ON THEIR PHYSICAL-CHEMICAL PROPERTIES
#54 | 2007-09-27Side-chain variants of redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
116493 ⎘